In colorectal and pancreatic cancer surgery, the intraoperative use of a fluorochrome-labeled anti-CEA monoclonal antibody, SGM-101, provides an enhanced differentiation between tumor and normal tissue [19]. The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.